Alioth Makes It onto the "KPMG China's 3rd Bio - Innovation Pioneer 50 Enterprises" List

For this year's evaluation, leading enterprises across multiple sub - sectors such as biopharmaceuticals, cell therapy and gene therapy, in - vitro diagnostics, medical devices, pharmaceutical outsourcing, AI - driven drug discovery, and traditional Chinese medicine innovation were selected based on six key dimensions: the leading - edge nature of technology and product lines, the richness of product pipelines and the proportion of in - house developed products, the backgrounds of the core management and R&D teams, industrialization prospects, the activity level in the capital market, and financial soundness. This initiative aims to create a resource - matching platform for biotechnology companies and assist biotech firms at various development stages in gaining greater market attention.

Alioth specializes in the development and application of pharmaceutical process filtration products and technologies based on new "filter membrane" materials. It is committed to providing high-quality separation and purification solutions that comply with domestic and international regulatory requirements for pharmaceutical enterprises. The company focuses on the pain points in the biopharmaceutical industry chain. Through continuous technological innovation and product iteration, it accelerates the breakthrough of "chokepoint" technologies in filter membrane materials, helps customers optimize filtration process plans, and safeguards the security of the pharmaceutical industry supply chain and the safe production of drugs.

Alioth has always been dedicated to meeting the unmet market demands in the field of membrane technology for pharmaceutical processes:

• Innovation at the material source to build a top-notch membrane material R&D system - Breakthroughs in sterilizing-grade filters and virus-removing filters: By innovating from the material origin, Alioth strives to establish a world-class membrane material R&D framework, achieving significant advancements in sterilizing-grade and virus-removing filters.
• Product capabilities on par with industry giants, along with a gradually improving product R&D and validation system - Authentic data and stable quality: Alioth boasts product performance comparable to that of industry leaders. It has been steadily refining its product R&D and validation processes, ensuring the delivery of products with authentic data and consistent quality.
• Access to top-tier clients, coupled with high-barrier and long-cycle data accumulation - Focusing on import substitution for molecules in Phase III clinical trials and commercialization: Alioth has gained entry to work with leading clients. Through the accumulation of high-barrier and long-cycle data, it concentrates on the import substitution of molecules in Phase III clinical trials and those in the commercialization stage.

This inclusion in the "Bio - Innovation Pioneer 50 Enterprises" list is a high recognition from the industry of Alioth's technological strength, product innovativeness, and industrial development potential. In the future, Alioth will uphold its innovative spirit, continuously strengthen breakthroughs in core technologies, accelerate the diversified layout of its product pipelines, and empower the high-quality development of the biomedical industry with more leading-edge filtration process solutions.